ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic NSCLC on entry into study suitable for pemetrexed therapy * Patients that meet one of the following criteria: - progressed following one prior platinum-based chemotherapy regimen for locally advanced or metastatic disease; -progressed within 6 months of adjuvant platinum-based chemotherapy * Life expectancy of \> 12 weeks Exclusion Criteria: * Prior treatment with pemetrexed in the last 12 months. * Prior therapy with an ET receptor antagonist * Any recent surgery, unhealed surgical incision, severe concomitant medical condition (eg, unstable cardiac, hepatic or renal disease) or significant laboratory finding which makes it undesirable for the patient to participate